RE:RE:RE:RE:RE:IBB almost FLATHi Adam, You are correct in your observation that many of the Fortune 500 achieved their membership in that exclusive club by such strategies. But there are other issues involved in M&A: targeting the right acquisition, valuation, tax structure, financing structure, due diligence, corporate integration.... to name a few. I am sure that you will agree that assessing the market value of AMCo is a complex undertaking and that is why much of the investment houses are on the sidelines. There is no such thing as "easy money" as you have said in an earlier post of yours when you declared that you had purchased more shares today.
Currently, the sentiment in the investment community is that pharma companies must solve problems and not just be cash generating machines but they must be innovation engines and must position themselves differently with patients, physicians and scientists than they have done in the past. Posters on this board are so emphatic that we are so different from Valeant, but yet the share price doesn't seem to be agreeing. And isn't price the final arbiter?
I am not asking that you share my opinion. All I ask is that you have a minuscule amount of respect and not proceed to accuse me of being an alias of notwrong here.
adamchess wrote: I am pretty sure that is how most large multi-national companies have grown to top 100 companies. As an accountant these companies make your head hurt how many subsidiaries they have. You guys are a one trick pony excuse for investors. Tomorrow you say leverage at low interest rates is great.
DeathPool wrote: debt.... growth by acquistion strategy ..... Are you just grasping this now, Adamchess?
We most swim do swim in the same ocean. And said someone once, you don't know who is swimming naked until the tide goes out.